Rapid Monitoring and Assessment of Tubercuolosis Treatment at the Point of Care Using Breath

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R41HL128991-01
Agency Tracking Number: R41HL128991
Amount: $224,770.00
Phase: Phase I
Program: STTR
Solicitation Topic Code: NHLBI
Solicitation Number: HL14-017
Solicitation Year: 2017
Award Year: 2015
Award Start Date (Proposal Award Date): 2015-09-01
Award End Date (Contract End Date): 2016-08-31
Small Business Information
615 ARAPEEN DR, STE 310, Salt Lake City, UT, 84108-1254
DUNS: 078475789
HUBZone Owned: N
Woman Owned: N
Socially and Economically Disadvantaged: N
Principal Investigator
 (404) 275-0755
Business Contact
Phone: (801) 410-7907
Email: swomitra@nanosynthsensors.com
Research Institution
 75 SOUTH 2000 EAST
SALT LAKE CITY, UT, 84112-8930
 Nonprofit college or university
DESCRIPTION provided by applicant Problem and Significance According to the CDC global statistics nearly of the world is infected with Tuberculosis TB In million f peopled infected lived in what is considered a high burden country Countries such as India Peru China sub Saharan Africa and others have significant regions endemic for TB particularly among the lower income population This represents a significant health problem that needs to be addressed Objective The objective of this proposal is to characterize and assess a rapid and portable TB treatment monitoring technology based on a solid state TB sensor that detects volatile organic biomarkers VOBs given off by the mycobacterium that cause TB VOBs are typically found in the breath of human beings and have known associations with many chronic and infectious diseases including TB The following VOBs are associated with TB methyl phenylacetate methyl p anisate methyl nicotinate and o phenylanisole Our prior supported research NSF STTR has shown that our newly developed sensor is capable of detecting these VOBs associated in a controlled environment The sensing material is made up of metal functionalized D TiO nanotube arrays that bind specific VOBs of interest based on the type of metal present The readout for the end user is an electronic signal that gives a rapid yes no answer based on change in current orders of magnitude change The sensor is simple to use completely inorganic requiring no specialized biological reagents for sensing i e antibodies fluorescent tags etc has a long shelf life over months uses a simple potentiostat for operation and is portable The intended use for this technology is for monitoring TB treatment at the point of care POC in a rapid manner to help ascertain if a treatment is working or help determine if a patient is subject to a drug resistant strain of TB In addition this sensing platfom integrates a data analytics platform that utilizes the electronics that operate the sensors smartphone potentiostat to collect patient demographics including time and geolocation of the diagnosis to allow health care workers and health departments to map out where TB is located in a population and where it could possibly spread This type of information in real time could be invaluable to health departments trying to manage a TB outbreak in a particular region Using VOBs for monitoring TB treatment is an attractive alternative to traditional methods i e sputum analysis clinical symptoms as it is can be detected using non invasive methods in a rapid manner Our preliminary results suggest a relationship between levels of VOBs present and if a medication is effective in treating a TB infection levels appear to reduce in days after treatment Ideally if this relationship holds true physicians could ascertain if a patient has a drug resistant strain of TB by simply measuring VOBs levels after a week of treatment instead of waiting several weeks for cultures results to get back as is currently done However VOBs have seen limited use in POC diagnostics settings since current technology Gas Chromatography Mass Spec for detection of VOBs is expensive and not suitable for low resource setting field use The technology presented here is low cost and can be tailored to detect VOBs of interest via specific metal functionalization and can overcome traditional technological hurdles associated with breath analysis To further develop this technology or TB treatment monitoring and provide comprehensive data analytics to healthcare workers the following hypothesis and specific aims must be looked at Hypothesis We hypothesize that the levels of VOBs for TB will decrease if drugs used to treat the infection are effective Hypothesis We also hypothesize that if the levels of VOBs are not reduced after administering treatment then this is indicative of multi drug resistant TB Specific Aim Determine the analytical validity the TB Breathalyzer device and determine the sensitivity and specificity of the sensor in reference to the andquot gold standardandquot used to monitor TB Hypothesis We hypothesize an integrated sensor and smartphone package will integrate into the flow of healthcare for physicians and analysis can be done quickly and easily with an intuitive app for operation and data collection Specific Aim Integrate sensor into a smartphone package and assess its performance including evaluating the user interface with clinicians to determine how the technology integrates into the flow of health care with physicians Hypothesis Integration of the sensor with a smartphone controller will allow healthcare professionals to collect data about patient demographics in real time which could provide important information for health care organization in regards to disease prevalence location stage of diseases and effectiveness of treatment Specific Aim Develop methods for real time data collection analysis and dissemination of the information for epidemiological tracking PUBLIC HEALTH RELEVANCE Tuberculosis TB kills millions of people each year This proposal will help develop methods for rapidly monitoring TB treatment using metal functionalized TiO nanotubes that are designed to specifically to sense electronically volatile organic biomarkers that are given off in the breath by the mycobacteria that cause TB In addition this technology will be integrated into a data analytics platform where patient demographic information can be overlaid with information on the effectiveness of patient treatment This data can be aggregated and mapped This will provide useful information on the effectiveness of treatment within a population and potentially predict where TB outbreaks may occur

* Information listed above is at the time of submission. *

Agency Micro-sites

SBA logo
Department of Agriculture logo
Department of Commerce logo
Department of Defense logo
Department of Education logo
Department of Energy logo
Department of Health and Human Services logo
Department of Homeland Security logo
Department of Transportation logo
Environmental Protection Agency logo
National Aeronautics and Space Administration logo
National Science Foundation logo
US Flag An Official Website of the United States Government